We systematically explored GIST resistance mechanisms to KIT-inhibitor TKIs that are either approved or under investigation in clinical trials: the studies draw upon GIST models and clinical trial correlative science. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.